In a new study that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have adapted a chemical approach to turn diseased cells into unique manufacturing sites for molecules that can treat a form of muscular dystrophy.
“We’re using a cell as a reaction vessel and a disease-causing defect as a catalyst to synthesize a treatment in a diseased cell,” said TSRI Professor Matthew Disney. “Because the treatment is synthesized only in diseased cells, the compounds could provide highly specific therapeutics that only act when a disease is present. This means we can potentially treat a host of conditions in a very selective and precise manner in totally unprecedented ways.”
The promising research was published recently in the international chemistry journal Angewandte Chemie.
Targeting RNA Repeats
In general, small, low molecular weight compounds can pass the blood-brain barrier, while larger, higher weight compounds tend to be more potent. In the new study, however, small molecules became powerful inhibitors when they bound to targets in cells expressing an RNA defect, such as those found in myotonic dystrophy.
Myotonic dystrophy type 2, a relatively mild and uncommon form of the progressive muscle weakening disease, is caused by a type of RNA defect known as a “tetranucleotide repeat,” in which a series of four nucleotides is repeated more times than normal in an individual’s genetic code. In this case, a cytosine-cytosine-uracil-guanine (CCUG) repeat binds to the protein MBNL1, rendering it inactive and resulting in RNA splicing abnormalities that, in turn, results in the disease.
In the study, a pair of small molecule “modules” the scientists developed binds to adjacent parts of the defect in a living cell, bringing these groups close together. Under these conditions, the adjacent parts reach out to one another and, as Disney describes it, permanently hold hands. Once that connection is made, the small molecule binds tightly to the defect, potently reversing disease defects on a molecular level.
“When these compounds assemble in the cell, they are 1,000 times more potent than the small molecule itself and 100 times more potent than our most active lead compound,” said Research Associate Suzanne Rzuczek, the first author of the study. “This is the first time this has been validated in live cells.”
The Latest on: Specific therapeutics
[google_news title=”” keyword=”Specific therapeutics” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Specific therapeutics
- Intensity Therapeutics, SAKK ink agreement to conduct phase 2 trial in early-stage breast cancer in Europe for INT230-6on May 13, 2024 at 12:30 am
Shelton, Connecticut Monday, May 13, 2024, 13:00 Hrs [IST] ...
- MC2 Therapeutics Receives Positive Feedback from FDA pre-IND Meeting and Updates on Indication Expansion Strategyon May 12, 2024 at 11:00 pm
Receives Positive Feedback from FDA pre-IND Meeting and Updates on Indication Expansion Strategy On track to file IND in mid-2025 for a Phase 2b clinical trial in Hidradenitis Suppurativa (“HS”) with ...
- Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicineson May 12, 2024 at 10:10 pm
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system ...
- Antisense and RNAi therapeutics Market Update Companies Showing Sign of Enormous Growthon May 12, 2024 at 2:55 pm
Global Antisense and RNAi therapeutics Market is valued approximately at USD 3.69 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 18.72% over the forecast period ...
- Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meetingon May 10, 2024 at 5:59 am
In vitro data showcases CNTY-101’s ability to induce CD19-specific cytolysis of B-cells and potential to treat B-cell driven autoimmune diseases ...
- Prelude Therapeutics Progresses in Cutting-Edge Cancer Treatment Developmenton May 10, 2024 at 3:00 am
Prelude Therapeutics Incorporated (Nasdaq: PRLD) recently shared its first quarter financial results. But even more newsworthy is the ongoing progress and future milestones slated for its novel ...
- Key Takeaways From C4 Therapeutics Analyst Ratingson May 9, 2024 at 11:20 am
In the assessment of 12-month price targets, analysts unveil insights for C4 Therapeutics, presenting an average target of $10.75, a high estimate of $14.00, and a low estimate of $8.00. This upward ...
- Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Icebergon May 9, 2024 at 6:32 am
Crispr Therapeutics AG shows potential for future earnings with its gene editing therapy Casgevy, offering treatment for various diseases. Read more here.
- Sex-Specific Brain Responses to Alcohol Cravingon May 6, 2024 at 2:02 pm
The study found that while alcohol cues triggered stronger cravings in men, stress cues had a similar impact on women, suggesting the need for sex-specific treatment strategies.
- New Therapeutic Promise For Fibromyalgiaon May 6, 2024 at 5:00 am
This month you might see the purple colors of Fibromyalgia Awareness Month, when people around the world try to raise awareness for fibromyalgia and other chronic pain conditions. The month is a time ...
via Bing News